Mangafodipir trisodium injection (Mn-DPDP). A contrast agent for abdominal MR imaging.
Mangafodipir trisodium (Mn-DPDP) is one of several recently developed targeted hepatobiliary agents. Contrast-to-noise measurements have shown favorable results for Mn-DPDP-enhanced MR as compared with nonenhanced T1- and T2-weighted images. An improved capability for lesion detection and the ability to characterize tumors of hepatocellular origin have been demonstrated. The prolonged enhancement obtained with Mn-DPDP provides an extended window of time during which effective contrast is maintained as compared with traditional extracellular contrast agents. This report details the experimental and initial clinical experience with Mn-DPDP-enhanced MR imaging of the abdomen.
Rofsky
N M
NM
Department of Magnetic Resonance Imaging, New York University Medical Center, New York, USA.
Earls
J P
JP
D000307:Adrenal Gland Diseases / Q000175:diagnosis; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003287:Contrast Media; D004492:Edetic Acid / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000175:diagnosis; D008099:Liver / Q000473:pathology; D008107:Liver Diseases / Q000175:diagnosis; D008113:Liver Neoplasms / Q000175:diagnosis; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008345:Manganese; D010182:Pancreatic Diseases / Q000175:diagnosis; D011732:Pyridoxal Phosphate / Q000031:analogs & derivatives*
D003287:Contrast Media; D008345:Manganese; D011732:Pyridoxal Phosphate; D004492:Edetic Acid; C060076:N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid